Patents by Inventor C. Frank Bennett

C. Frank Bennett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10619158
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: April 14, 2020
    Assignee: IONIS Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Patent number: 10584336
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: March 10, 2020
    Assignee: Regulus Therapeutics Inc.
    Inventors: C. Frank Bennett, Susan M. Freier, Richard H. Griffey
  • Patent number: 10577604
    Abstract: Disclosed herein are methods for monitoring expression of C9ORF72 mRNA and protein in an animal with C9ORF72 specific inhibitors. Such C9ORF72 specific inhibitors include antisense compounds.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: March 3, 2020
    Assignees: Ionis Pharmaceuticals, Inc., The Johns Hopkins University
    Inventors: C. Frank Bennett, Susan M. Freier, Jeffrey D. Rothstein, Christopher Donnelly, Rita G. Sattler
  • Publication number: 20200032260
    Abstract: The present disclosure provides compounds comprising oligonucleotides complementary to a portion of the IKBKAP gene. Certain such compounds are useful for hybridizing to a portion of the IKBKAP gene, including but not limited to a portion of the IKBKAP gene in a cell. In certain embodiments, such hybridization results in modulation of splicing of the IKBKAP gene. In certain embodiments, the IKBKAP gene includes a mutation that results in defective splicing and a truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in a decrease in the amount of defective splicing and truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in an increase in the amount of normal splicing and functional, full-length IKAP protein. In certain embodiments, oligonucleotides are used to treat Familial Dysautonomia.
    Type: Application
    Filed: May 24, 2019
    Publication date: January 30, 2020
    Inventors: C. Frank Bennett, Frank Rigo, Adrian R. Krainer, Rahul Sinha
  • Publication number: 20200032257
    Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Application
    Filed: March 11, 2019
    Publication date: January 30, 2020
    Inventors: Timothy M. Miller, Sarah Devos, C. Frank Bennett, Frank Rigo
  • Patent number: 10533178
    Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: January 14, 2020
    Assignees: Ionis Pharmaceuticals, Inc., University of Utah Research Foundation
    Inventors: C. Frank Bennett, Susan M. Freier, Stefan M. Pulst, Daniel R. Scoles, Gene Hung
  • Patent number: 10526604
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of a nrRNA in an animal. Also provided herein are methods, compounds, and compositions for treating, ameliorating, delaying or reducing a symptom of a disease or disorder associated with a nuclear-retained RNA in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate a disease or condition associated with a nuclear-retained RNA, or a symptom thereof.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: January 7, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Huynh-Hoa Bui, Kenneth W. Dobie
  • Publication number: 20190382751
    Abstract: The present disclosure provides compounds comprising modified oligonucleotides for use in CRISPR. In certain embodiments, such modified oligonucleotides provide improved properties of crRNA.
    Type: Application
    Filed: December 28, 2017
    Publication date: December 19, 2019
    Applicants: Ionis Pharmaceuticals, Inc., Ludwig Institute for Cancer Research
    Inventors: Meghdad Radhar, Thazha P. Prakash, Eric E. Swayze, C. Frank Bennett, Moira A. McMahon
  • Publication number: 20190323013
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: November 29, 2018
    Publication date: October 24, 2019
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Freier
  • Publication number: 20190249177
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: February 8, 2019
    Publication date: August 15, 2019
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Patent number: 10344282
    Abstract: The present disclosure provides compounds comprising oligonucleotides complementary to a portion of the IKBKAP gene. Certain such compounds are useful for hybridizing to a portion of the IKBKAP gene, including but not limited to a portion of the IKBKAP gene in a cell. In certain embodiments, such hybridization results in modulation of splicing of the IKBKAP gene. In certain embodiments, the IKBKAP gene includes a mutation that results in defective splicing and a truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in a decrease in the amount of defective splicing and truncated IKAP protein. In certain embodiments, hybridization of oligonucleotides complementary to a portion of the IKBKAP gene results in an increase in the amount of normal splicing and functional, full-length IKAP protein. In certain embodiments, oligonucleotides are used to treat Familial Dysautonomia.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: July 9, 2019
    Assignees: IONIS PHARMACEUTICALS, INC., COLD SPRING HARBOR LABORATORY
    Inventors: C. Frank Bennett, Frank Rigo, Adrian R. Krainer, Rahul Sinha
  • Patent number: 10301627
    Abstract: Provided herein are methods for the treatment of liver cancer. These methods encompass the administration of a compound comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Also provided herein are compositions for the treatment of liver cancer. Such compositions include compounds comprising a modified oligonucleotide, wherein the modified oligonucleotide is targeted to a miRNA. Certain miRNAs have been identified as overexpressed in liver cancer, such as, for example, hepatocellular carcinoma, and are thus selected for targeting by modified oligonucleotides. Further, certain miRNAs have been identified as overexpressed in hepatocellular carcinoma cells exposed to dioxin, and are thus selected for targeting by modified oligonucleotides. Antisense inhibition of certain of these miRNAs has been found to inhibit cell proliferation and induce apoptosis.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: May 28, 2019
    Assignees: Regulus Therapeutics Inc., Rosetta Genomics Ltd.
    Inventors: C. Frank Bennett, Ayelet Chajut, Christine Esau, Eric Marcusson, Noga Yerushalmi
  • Publication number: 20190142856
    Abstract: Provided are methods for reducing the amount or activity of C90RF72 RNA, and in certain instances of reducing the amount of C90RF72 protein, in an animal. Such methods are useful to prevent or ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include anxiety, reduced spatial learning, and memory loss. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), corticalbasal degeneration syndrome (CBD), atypical Parkinsonian syndrome, and olivopontocerellar degeneration (OPCD).
    Type: Application
    Filed: April 13, 2017
    Publication date: May 16, 2019
    Applicants: Ionis Pharmaceuticals, Inc., Ludwig Institute for Cancer Research
    Inventors: C. Frank Bennett, Frank Rigo, Don W. Cleveland, Jie Jiang, Qiang Zhu, Clotilde Lagier-Tourene
  • Patent number: 10273474
    Abstract: Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: April 30, 2019
    Assignees: WASHINGTON UNIVERSITY, ISIS PHARMACEUTICALS, INC.
    Inventors: Timothy M. Miller, Sarah Devos, C. Frank Bennett, Frank Rigo
  • Publication number: 20190062744
    Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.
    Type: Application
    Filed: September 6, 2018
    Publication date: February 28, 2019
    Applicant: Regulus Therapeutics Inc.
    Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
  • Patent number: 10202603
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: February 12, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • Publication number: 20190040384
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Application
    Filed: February 28, 2018
    Publication date: February 7, 2019
    Applicant: Biogen MA Inc.
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo
  • Publication number: 20190030058
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
    Type: Application
    Filed: February 9, 2018
    Publication date: January 31, 2019
    Applicants: Biogen MA Inc., Cold Spring Harbor Laboratory
    Inventors: C. Frank Bennett, Gene Hung, Frank Rigo, Adrian R. Krainer, Yimin Hua, Marco A. Passini, Lamya Shihabuddin, Seng H. Cheng, Katherine W. Klinger
  • Publication number: 20190017047
    Abstract: Disclosed herein are methods for decreasing Ataxin 2 mRNA and protein expression. Such methods are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotrophic lateral sclerosis (ALS), and parkinsonism.
    Type: Application
    Filed: May 7, 2018
    Publication date: January 17, 2019
    Applicants: Ionis Pharmaceuticals, Inc., University of Utah Research Foundation
    Inventors: C. Frank Bennett, Susan M. Freier, Stefan M. Pulst, Daniel R. Scoles, Gene Hung
  • Patent number: RE47320
    Abstract: Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40 include hyperproliferative disorders, graft versus host disease (GVHD), graft rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and certain forms of arthritis.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: March 26, 2019
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Lex M. Cowsert, Susan M. Freier